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Background: Publications on autoantibodies to tumour-associated antigens (TAAs) have failed to show either
calibration or reproducibility data. The validation of a panel of six TAAs to which autoantibodies have been described is
reported here.
Materials and methods: Three separate groups of patients with newly diagnosed lung cancer were identiﬁed,
along with control individuals, and their samples used to validate an enzyme-linked immunosorbant assay. Precision,
linearity, assay reproducibility and antigen batch reproducibility were all assessed.
Results: For between-replicate error, samples with higher signals gave coefﬁcients of variation (CVs) in the range
7%–15%. CVs for between-plate variation were only 1%–2% higher. For between-run error, CVs were in the range
15%–28%. In linearity studies, the slope was close to 1.0 and correlation coefﬁcient values were generally >0.8. The
sensitivity and speciﬁcity of individual batches of antigen varied slightly between groups of patients; however, the
sensitivity and speciﬁcity of the panel of antigens as a whole remained constant. The validity of the calibration system
was demonstrated.
Conclusions: A calibrated six-panel assay of TAAs has been validated for identifying nearly 40% of primary lung
cancers via a peripheral blood test. Levels of reproducibility, precision and linearity would be acceptable for an assay
used in a regulated clinical setting.
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introduction
Lung cancer is the highest cause of death from cancer
worldwide, responsible for the deaths of >1 million men and
women every year [1]. Lung cancer is often detected on chest
X-ray, but by this time, the cancer is usually advanced and few
patients are cured by treatment. However, if diagnosed early,
the chances of cure are 90%. At present, there is no early
detection test or acceptable screening method for this disease;
therefore, there is an urgent need to produce a screening test
that can identify the cancer in its early curable stage, especially
in high-risk individuals.
Circulating antibodies which react with tumour-associated
antigens (TAAs) have been found in serum samples from
patients with a variety of cancers, including lung cancer [2–10],
and may represent an early indicator of the presence of cancer.
It has been hypothesised that the heterogeneity of antigen
expression will mean that a panel of assays for autoantibodies
of various TAA speciﬁcities will be needed for effective
detection of lung cancer [11]. Recent publications have
conﬁrmed that measuring autoantibodies to a panel of antigens
gives a signiﬁcantly greater level of sensitivity compared with
that for a single antigen [5–10].
Autoantibodies have been found in the blood of patients who
develop lung cancer up to 5 years before screening spiral
computed tomography scans were able to detect the tumour
[2]. Consequently, monitoring people at increased risk of lung
cancer for the presence of serum autoantibodies may enable
earlier detection of the disease, allowing earlier therapeutic
intervention.
This article reports the laboratory validation data and
performance characteristics for a serum autoantibody test panel
consisting of six TAAs to which autoantibodies have been
described. The antigens are p53, NY-ESO-1, cancer-associated
antigen (CAGE), GBU4-5, Annexin 1 and SOX2, and the samples
are from patients with or without newly diagnosed lung cancer.
Speciﬁcally, we address the development of quality assurance in
reagent preparation, analyte calibration and quality-control (QC)
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carried out in a clinical laboratory setting.
materials and methods
production of recombinant antigens for autoantibody
assays
vector construct. Speciﬁc complementary DNA (cDNA) for p53, NY-ESO-1,
CAGE, GBU4-5 and Annexin 1 were sub-cloned into the pET21b expression
vector (which had previously been engineered to also express a BirA tag). The
speciﬁc cDNA for SOX2 was sub-cloned into the pET44b expression vector
(expressing a NusA tag) (Novagen, Darmstadt, Germany).
expression of recombinant proteins/antigens. The recombinant proteins were
expressed in BL21(DE3) bacteria (Novagen), grown in terriﬁc broth (TB) or
autoinduction TB media (Novagen), and puriﬁed using HisTrap afﬁnity
columns (GE Healthcare, Uppsala, Sweden) according to manufacturers’
protocols. Negative control proteins consisting of either BirA or NusA alone
were also produced. Antigens were produced by one of the two external
manufacturers,exceptinthecaseofonestudyforwhichSOX2wasproducedby
Oncimmune Ltd. Details of the antigens used for each study are given in the
supplemental Table S1 (available at Annals of Oncology online).
patients
Three separate groups of patients with newly diagnosed lung cancer were
identiﬁed (supplemental Table S1, available at Annals of Oncology online).
Group 1 contained 145 lung cancer patients (median age 66; range 41–87)
and 146 normal controls (median age 66; range 41–87). Similarly, group 2
had 241 (63; 28–87) and 240 (63; 28–87), respectively, while group 3 had
269 (65; 38–87) and 269 (65; 38–86). All patients with lung cancer were as
far as possible individually matched by sex, age and smoking history to
a control individual with no previous history of malignant disease. In
patients with lung cancer, blood samples were obtained after diagnosis but
before receiving any anticancer treatment. Samples were obtained, with full
informed consent, from the enrolment sites.
assay procedure
A semi-automated indirect enzyme-linked immunosorbant assay was
utilised (all liquid-handling steps were carried out using an automated
liquid-handling system). Puriﬁed recombinant antigens were diluted to
provide a semi-log titration series for each antigen ranging from 160 to
1.6 nM. Control antigens (BirA and NusA) were also included to allow
subtraction of the signal due to nonspeciﬁc binding to bacterial
contaminants. Antigen dilutions were passively adsorbed to the surface of
microtitre plate wells in high phosphate buffer overnight at room
temperature. After washing in phosphate-buffered saline containing 0.1%
Tween 20 (pH 7.6), microtitre plates were blocked with a gelatine-based
blocking buffer. Coated plates were found to be stable for at least 48 h after
coating if washed and stored at 4 C in the presence of blocking buffer
(Oncimmune Ltd, data on ﬁle). Serum samples (diluted 1 in 110 in
a blocking buffer) were then added to the plates and allowed to incubate at
room temperature with shaking for 90 min. Following incubation, plates
were washed and horseradish peroxidase (HRP)-conjugated rabbit anti-
humanIgG(Dako,Glostrup,Denmark)wasadded.Aftera60-minincubation
with shaking, the plates were washed and 3,3#,5,5#-tetramethylbenzidine was
added. The optical density (OD) of each well was determined
spectrophotometrically at650nm aftera 15-minincubation.Control platesto
which antigen-speciﬁc mAbs or an anti-His tag mAb (Novagen) had been
added in place of serum were included to validate that the plate coating had
been successful and antigen immunoreactivity had been maintained. These
plates were probed with rabbit anti-mouse Ig-HRP (Dako).
calibration. Calibration standards of known potency are not available for
assays to measure autoantibodies against TAAs. Therefore, a calibration
system was devised in which ﬂuids that drained from pleural or ascitic
cavities of patients with lung cancer were screened for autoantibody reactivity
[12]. Those found to be positive for the TAAs of interest were taken forward
for further development. Speciﬁcity of the autoantibody reactivity in these
ﬂuids was assessed with recombinant TAAs and conﬁrmed by western
blotting. For each ﬂuid, a calibration curve of background-corrected OD
versus log dilution was constructed to which a four-parameter logistic model
plot was ﬁtted (median r
2 > 0.99) [13]. The OD value for each unknown
sample was then converted to a calibrated log reference unit (RU) using the
calibration curve. An optimum dilution range for each antigen was
determined in order to give acceptable calibration precision (<20%). The
range corresponded to 7.5%–92.5% of the upper asymptote of the average
calibration curve, giving a range of 5.0 natural log units.
Apart from the validation studies, the calibration system was only
evaluated for group 3 samples. A calibration curve was prepared at the
beginning of every assay run.
test result. Samples were judged to be positive for the presence of
autoantibody when they (i) showed a dose response to the antigen titration
seriesand(ii)had asignalwhichwasabovetheacceptedcut-pointforanassay
to one or more of the antigens. Cut-points were originally derived in terms of
ODs(mean63SD)butthenintermsofRUswhenthecalibrationsystemhad
been developed. A positive test result for the panel was deﬁned as a positive
autoantibody response to at least one of the six TAA antigens in the panel.
assay validation
precision. The intra-assay precision for this assay was on the basis of
variation between replicates on the same plate (within plate) and between-
plate run on the same day (between plate). Interassay precision
(intermediate ‘between-run’ reproducibility) for each antigen in the assay
was on the basis of variation over days within the same study (between
run).
Variance components and coefﬁcients of variation (CVs) were estimated
using standard analysis of variance methods. Separate calculations were
carried out on antilogged RU values for samples with high, medium and
low signals. The high and medium signals generally spanned the diagnostic
test cut-point values.
Since independent reference materials of known concentration were not
available for these assays, it was not possible to assess accuracy.
linearity. Linearity was assessed by a serum dilution study using two serum
samples for each of the six antigens under the assumption that the top
concentration gave 100% recovery. A doubling dilution series was prepared
for each sample. The panel of autoantibody assays was carried out on each
dilution and the OD measured. The dilution was estimated from the
relevant calibration curve and a plot of the estimated versus the actual
(known) dilution was constructed. The slope and intercept were estimated
using linear regression and the goodness of ﬁt assessed using the linear
correlation coefﬁcient. A slope of between 0.8 and 1.2, an intercept within
0.1 of zero and a correlation coefﬁcient of at least 0.8 were required for
satisfactory linearity.
QC monitoring. Six high-signal QC serum samples, one for each antigen,
were interspersed amongst test samples in a series of studies carried out
over a 14-week period. The results were compared with their respective
expected values as established in preliminary studies. This enabled the QC
sera to be monitored over time to evaluate their reproducibility using
Levey–Jennings plots. The usual mean 6 3 SD chart limits were adjusted to
mean 6 3.5 SD for the QC of six separate antigens.
assay reproducibility. The sensitivity and speciﬁcity for lung cancer of each of
theindividualautoantibodyassaysaswellasthepanelwereassessedforeachof
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background-correctedODdata, whereas valuesfor group 3 were derived from
datatowhichcalibrationhadbeenappliedinordertoobtainmeasurementsin
RUs. For each assay, a test cut-point of mean 6 3 SD was used.
Between-run reproducibility was also assessed using concordance rates,
i.e. the percentage of samples where the calibrated result, measured in RUs,
was the same (i.e. positive or negative) on two runs carried out on separate
days. Calibrated Annexin 1 results were not available for one of the two
runs in this particular study, so between-run reproducibility is reported for
the other ﬁve assays in group 3.
antigen batch reproducibility. The capture antigen is the most critical
reagent in the autoantibody assay and, as such, it is essential that
reproducibility between batches be demonstrated.
A subset of the group 3 samples was run in an assay constructed with
four different batches of CAGE as the capture antigen. These four different
batches had been obtained from the same supplier over a 3-month period
and had been produced and puriﬁed from four different fermentation runs.
The mean calibrated signal for cancer and normal groups, and the
sensitivity/speciﬁcity, was compared across batches.
results
precision
For measurement of within-plate variation, samples with
high signals gave CVs in the range 7%–15% (Table 1).
As expected, for samples with medium signals, CVs were
higher, in the range 9%–23%. Samples with low signals (not
presented) generally gave CVs > 20%, increasing as the mean
OD approached zero.
For between-plate variation (not presented), CVs were only
1%–2% higher than for between-replicate error, indicating
very little additional variability due to plate-to-plate
differences.
For measurement of between-run variation, high-signal
samples gave an average CV of 19% (range 15%–28%)
(Table 1). Again as expected, for samples with medium
signals, the average CV was higher at 28% (range 22%–42%).
Samples with low signals generally gave CVs > 30%. These
ﬁgures indicate signiﬁcant additional variation due to run-
to-run effects, increasing the CV by roughly 10% (Table 1).
This amount is typical for assay work.
linearity
For all samples, the slope estimate was close to 1.0 and the
intercept close to zero (Table 2; Figure 1), thereby indicating
a linear assay. Correlation coefﬁcients (r) were >0.83 in all but
one case (Annexin 1: sample C6; r = 0.77), with a median of
0.98, thereby demonstrating satisfactory goodness of ﬁt.
QC monitoring
The plots of calibrated results (RUs) versus time (Figure 2)
showed that all QC serum control values for each of the six
antigens fell within the standard deviation limits,
demonstrating that the calibration system was effective in
producing stable day-to-day QC results.
assay reproducibility
The sensitivity and speciﬁcity of each autoantibody assay as
well as the panel for each of the sample groups are
summarised in the supplemental Table S2 (available at Annals
of Oncology online). The overall panel sensitivities and
speciﬁcities were very similar between groups, demonstrating
the validity of the calibration system and the robustness of the
assay.
Using concordance data, the reproducibility of the calibrated
panel (group 3) was conﬁrmed as >95%. The number of
samples that changed status (i.e. positive or negative) ranged
from 0.5% to 2.4% per antigen. When categorised by cancer or
Table 2. Linearity analysis: summary by antigen and sample
Control sample A Control sample B
Sample Initial OD
a Slope, intercept r Sample Initial OD Slope, intercept r
p53 C1 0.20 0.83, 0.13 0.91 C5 0.55 0.96, 0.03 0.99
SOX2 C1 0.06 0.97, 20.10 0.86 C4 0.62 0.99, 20.02 0.97
CAGE C2 0.90 0.97, 0.06 0.99 C3 0.72 0.97, 0.04 0.99
NY-ESO-1 C3 0.49 0.98, 0.06 0.98 C4 0.28 0.98, 0.03 0.98
GBU4-5 C1 0.19 0.93, 0.00 0.94 C2 0.20 1.01, 0.05 0.91
Annexin 1 C1 0.31 0.96, 0.04 0.98 C6 0.26 0.86, 0.11 0.77
Average standard error of the slope estimate = 0.09.
OD, optical density; r, correlation coefﬁcient.
aBackground-corrected OD at initial dilution.
Table 1. Between-replicate precision and intermediate reproducibility
estimates
Medium signal High signal
Mean OD CVe
(%)
CVr
(%)
Mean OD CVe
(%)
CVr
(%)
p53 0.17 17 22 0.38 12 17
SOX2 0.31 10 42 0.38 11 28
NY-ESO-1 0.35 9 25 0.69 11 18
CAGE 0.23 13 24 0.43 7 16
GBU4-5 0.10 23 31 0.35 9 15
Annexin 1 0.13 20 26 0.25 15 21
Average 15 28 11 19
OD means on the basis of 216 observations and 12 runs each; CVs on the
basis of mean of two replicates of antilogged RU values.
OD, optical density; CVe, between-replicate CV; CVr, between-run CV
(including intra-assay component); CVs, coefﬁcients of variation; RU,
reference unit.
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antigen batch reproducibility
The characteristics of the assays run on a subset of group 3
samples using four different batches of CAGE antigen are
summarised in Table 3. The mean calibrated signals for cancers
and normal groups were similar across batches, demonstrating
the effectiveness of the calibration system. The sensitivity and
speciﬁcity of individual batches of antigen was also very similar,
as was the sensitivity and speciﬁcity of the panel of antigens as
a whole, demonstrating the robustness of an assay on the basis
of a panel approach.
discussion
Assays used to measure serum antibodies for the diagnosis and
management of autoimmune disease often employ World
Health Organization (WHO) standards as calibration materials
[14, 15]. These are usually derived from human serum or
plasma (WHO website: http://www.who.int/bloodproducts/
ref_materials/en/). As such, issues of longevity arise with new
Figure 1. Linearity plots of estimated versus actual dilution (one sample for each antigen).
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introduced on a regular basis.
The ﬂuids used as calibrator material in our study were
drained from the pleural cavities of patients suffering from lung
cancer as part of the normal course of their disease
management. Use of these ﬂuids provided a long-term source
of calibrator material so that the inevitable difﬁculties
encountered with sourcing and validating new materials could
be avoided for as long as possible and the reproducibility of the
assay result over months or even years could be assured.
Although every effort was made to ensure that the ﬂuids were
stored under conditions that would not allow their reactivity to
deteriorate, a study is underway to investigate the stability of
pleural ﬂuids as calibrator materials under long-term storage.
The optimised dilution of sera used (Oncimmune Ltd, data
on ﬁle), together with the use of an anti-human IgG-HRP
conjugate detection system, is considered important in the
development of this test. They optimise detection of relevant
autoantibodies while minimising detection of low-titre
nonspeciﬁc antibodies (known to accumulate with advancing
age) and poly-reactive IgM antibodies [16, 17].
Linearity is often difﬁcult to demonstrate in serology assays
and can show wide variability between assays [18]. However,
we report good assay linearity with a slope close to 1 and a high
correlation coefﬁcient for all samples. We have also shown that
the assay has CVs generally <15% and <25% for intra- and
interassay precision, respectively. This is in line with that
reported for measurement of serum autoantibodies in patients
with benign autoimmune disease [19, 20]. Three discrete sets of
clinical samples (totalling 655 cancers and 655 normals) were
used for clinical validation of the assay. The sensitivity and
speciﬁcity was shown to be in the region of 40% and 90%,
respectively, for all three groups, demonstrating the
reproducibility and robustness of this assay system. The fact
Figure 2. Levey–Jennings plots of control sera for each antigen over a 14-week period.
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same sensitivity and speciﬁcity as the uncalibrated data for
groups 1 and 2 provides evidence that the calibration system
was effective. This is further supported by the concordance data
and Levey–Jennings plots which show good assay stability and
reproducibility within studies and over several months.
To the authors’ knowledge, this is the ﬁrst publication to
report an assay to detect autoantibodies against TAAs that has
clearly demonstrated linearity, precision and reproducibility
sufﬁcient for use in the clinical setting. These data conﬁrm the
reproducibility of this panel of autoantibodies for identifying
almost 40% of primary lung cancers through a peripheral blood
test. The similar sensitivities and speciﬁcities measured for
these three datasets and with different batches of proteins
utilised in the assays emphasise the robustness of these
autoantibody assays.
These data also conﬁrm the value of a panel of
autoantibodies over a single autoantibody assay. The small
variations in sensitivity and speciﬁcity of single antigens
between different studies could be attributed to the use of
completely different sample sets. However, the attraction of the
panel approach is that when the same antigens are used, the
overall sensitivity and speciﬁcity remains constant even in
discrete populations.
We have also shown reproducibility between four batches of
an antigen (CAGE) in the calibrated assay. This shows stability
of the results between protein batches. These data have allowed
us to devise formal procedures for antigen batch veriﬁcation
and release that will ensure that all the required QC criteria are
met and that an antigen batch is validated before it is released
for use in the assay. This will ensure continuity of results across
multiple antigen batches.
conclusions
The performance characteristics of an assay for the measurement
of autoantibodies against a panel of antigens known to be
expressed in lung cancer have conﬁrmed its reproducibility for
identifying nearly 40% of primary lung cancers through
a peripheral blood test. The levels of reproducibility, precision
and linearity would be acceptable for an assay used in
a regulated clinical setting. A simple blood test that is both
reliable and reproducible, such as that described here, represents
a potential aid to imaging modalities. This assay has now been
commercialised and will be used as a ‘platform technology’ that
is technically valid for identifying all types of solid tumours.
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